top of page
Home
Purpose
People
Pipeline
Press
Contact
Praetego
Mar 1, 2023
FUNDING AWARDS
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy
Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M
Praetego
Oct 4, 2022
FUNDING AWARDS
Praetego Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer’s Disease
Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to anno
Praetego
Sep 30, 2020
FUNDING AWARDS
NIH Phase 2 STTR Funding Award
Praetego Inc. is pleased to announce the approval of a multi-year $2.1M STTR grant from the National Institute of Diabetes and Digestive and
Praetego
Jan 2, 2020
FUNDING AWARDS
Phase 2 grant submitted to NIH/NIDDK
After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant.
Press + Announcements
Praetego’s progress is routinely updated as we strive to enter clinical trials. Please check back frequently for news, announcements, and events.
Home
Purpose
People
Pipeline
Press
Contact
bottom of page
